GlassScriptPhysician profile
Sara Kulangara
NPI 1487658464
$1,532.18
in general payments reported to CMS, 2019-2025
22 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $137 · 2021: $28.82 · 2022: $85.40 · 2023: $294 · 2024: $305 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $416.82 | 2019-2025 | |
| Amgen INC. | $191.34 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $180.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $90.10 | 2023-2025 | Verquvo |
| Becton, Dickinson and Company | $89.31 | 2020 | |
| Scpharmaceuticals INC. | $83.95 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $72.19 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $47.29 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.85 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $39.72 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $37.39 | 2024 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $34.02 | 2024 | Wainua, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.04 | 2019-2023 | Lifevest |
| Novo Nordisk INC | $24.98 | 2024 | Ozempic, Rybelsus |
| Recor Medical INC | $23.34 | 2024 | Paradise Renal Denervation System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $22.33 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $21.35 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.29 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $16.31 | 2019 | |
| Esperion Therapeutics, INC. | $15.87 | 2021 | |
| Daiichi Sankyo INC. | $15.35 | 2025 | Injectafer |
| Lundbeck LLC | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Kulangara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.